2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
John M. Burke, MD, Elias Jabbour, MD, Rami S. Komrokji MD, and Shaji Kumar, MD, review data from key hematologic malignancies presentations at the 2016 American Society of Clinical Oncology Annual Meeting.
John M. Burke, MD
Elias Jabbour, MD
Rami S. Komrokji, MD
Shaji K. Kumar, MD

Hematologic Malignancies

Randomized phase III investigation of CPX-351 vs “7 + 3” induction identified a potential new standard of care for older patients with previously untreated high-risk AML.

Released: June 8, 2016

Fractionated dosing of CTL019 minimized CRS-related toxicity and maintained high response rates in patients with relapsed/refractory CD19+ ALL.

Released: June 6, 2016

Preinfusion disease burden associated with increased rates of cytokine release syndrome after 19-28z CAR-modified T-cell therapy.

Released: June 6, 2016

Early-phase study suggests promise of venetoclax plus low-dose cytarabine in untreated elderly patients with acute myeloid leukemia.

Released: June 6, 2016

Long-term analysis shows durable reductions in splenomegaly and significantly prolonged survival with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Released: June 7, 2016

This propensity score analysis comparing 2 phase II studies shows improved EFS and OS with addition of ponatinib vs dasatinib to standard HCVAD chemotherapy in newly diagnosed Ph+ ALL.

Released: June 13, 2016

Mogamulizumab produces clinical response in a population of adult patients with relapsed/refractory ATL who currently have no consensus treatment options.

Released: June 7, 2016

Early investigation of lenalidomide in a patient population with a poor prognosis demonstrates tolerability with some durable responses.

Released: June 14, 2016

Phase II data demonstrate that venetoclax monotherapy is active in patients with R/R CLL and prior treatment with either ibrutinib or idelalisib, including those with refractory disease.

Released: June 6, 2016

Early investigation of the next-generation BTK inhibitor acalabrutinib suggests that this agent can be used safely and has promising activity in previously untreated CLL patients, with no disease progression observed at a median follow-up of 10.5 months.

Released: June 8, 2016

Study confirmed a continued role for upfront ASCT in fit patients with newly diagnosed MM.

Released: June 7, 2016

A meta-analysis of 3 phase III trials shows lenalidomide maintenance after ASCT significantly increased OS by an estimated 2.5 yrs vs placebo or no maintenance in patients with newly diagnosed multiple myeloma.

Released: June 6, 2016

Early-phase data from a single-arm study demonstrate favorable safety and efficacy for the KPd combination in a population of patients with relapsed/refractory MM who were largely refractory to lenalidomide.

Released: June 6, 2016

Early-phase study of pembrolizumab plus lenalidomide plus dexamethasone in heavily pretreated MM showed 50% ORR, including a 38% rate in lenalidomide-refractory patients.

Released: June 8, 2016

Early study of venetoclax in combination with bortezomib/dexamethasone yields ORR in more than 80% of patients with R/R MM not refractory to bortezomib.

Released: June 9, 2016

The current modeling analysis shows that the addition of carfilzomib to lenalidomide/dexamethasone provides an additional 1.99 LYs and 1.67 QALYs vs lenalidomide/dexamethasone, as well as providing an ICER that ranges between $74,000 and $109,000.

Released: June 10, 2016

Addition of carfilzomib to lenalidomide/low-dose dexamethasone improved PFS and ORR in patients with MM who relapsed within 1 year after first previous therapy or transplantation.

Released: June 14, 2016

Here are expert thoughts on the hematologic malignancies abstracts from ASCO 2016 that have the most potential to change clinical practice.

Shaji K. Kumar, MD Released: May 31, 2016

John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, provide an analysis of key presentations on hematologic malignancies from the 2016 clinical oncology meeting in Chicago.

John M. Burke, MD Elias Jabbour, MD Rami S. Komrokji, MD Shaji K. Kumar, MD Physicians: maximum of 2.5 AMA PRA Category 1 Credits Released: September 8, 2016 Expired: No longer available for credit

The investigators of this randomized phase III trial suggest that adding daratumumab to bortezomib/dexamethasone should be considered as a new standard of care for patients with relapsed/refractory multiple myeloma.

Released: June 8, 2016

John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, provide an analysis of key presentations on hematologic malignancies from the 2016 clinical oncology meeting in Chicago.

Released: August 30, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue